HK inno.N announced on the 22nd that it has completed enrollment of subjects for the domestic Phase 3 clinical trial of its new GLP-1 receptor agonist obesity treatment “IN-B00009 (generic name: ecnoglutide).”

HK inno.N received approval for the Phase 3 clinical trial plan (IND) for IN-B00009 from the Ministry of Food and Drug Safety in May last year, and completed enrollment of the target 313 subjects approximately four months after initiating the first subject registration in September of the same year. HK inno.N plans to complete a total of 40 weeks of dosing within this year and then promptly proceed with the marketing authorization application process.

This Phase 3 clinical trial is being conducted at 24 medical institutions nationwide, including Kangbuk Samsung Hospital, and targets Korean adult patients with obesity or overweight without accompanying diabetes. Subjects will receive either IN-B00009 or placebo via subcutaneous injection once weekly, and will be evaluated for efficacy and safety. The primary endpoints are the percentage change in body weight at week 40 from baseline and the proportion of subjects who achieve at least a 5% reduction in body weight.

IN-B00009 is a GLP-1 receptor agonist developed by global biopharmaceutical company Sciwind Biosciences Co., Ltd., and HK inno.N secured domestic development and commercialization rights to the compound in 2024. It is currently under development as both an obesity treatment and a diabetes treatment.

With the increase in the domestic population with obesity, the obesity treatment market is also growing rapidly. According to pharmaceutical market research firm IQVIA, the domestic obesity treatment market size in the first half of last year was approximately KRW 270 billion, a 51% increase compared with the same period a year earlier.

An HK inno.N official said, “In line with the rapid growth of the obesity treatment market, the company will make every effort to ensure that IN-B00009 can establish itself as a new treatment option in the domestic obesity treatment market.”

Popular News